Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Leoben – page 30

426 clinical trials in Leoben, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Leoben at a glance
426
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

426 trials in Leoben

Open in trial search

Hidradenitis

Not recruiting

Study on the Effectiveness of Ianalumab for Treating Moderate to Severe Hidradenitis Suppurativa in Patients

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ianalumab
  • Sponsor:Novartis Pharma AG

Dermatitis atopic

Not recruiting

Study on the Effectiveness and Safety of Lebrikizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

Study of Osimertinib and Chemotherapy for Patients with EGFR Mutation Positive Resectable Non-Small Cell Lung Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Astrazeneca AB

Uveal melanoma+2

Not recruiting

Study on the Effectiveness and Safety of Belzupacap Sarotalocan for Patients with Small Choroidal Melanoma or Indeterminate Lesions

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Belzupacap Sarotalocan
  • Sponsor:Aura Biosciences Inc.

Cervix carcinoma

Not recruiting

Study of Chemoradiotherapy With or Without Pembrolizumab for Patients With High-Risk, Locally Advanced Cervical Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Plasma cell myeloma

Not recruiting

Study Comparing ABBV-383 with Standard Therapies for Adults with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on Dabigatran and Phenprocoumon for Treating Left Ventricular Thrombosis After Heart Attack in Patients with STEMI

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Medical University Of Graz

Study of Tarlatamab for Patients with Limited-Stage Small-Cell Lung Cancer After Chemoradiotherapy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Argipressin
  • Sponsor:Amgen Inc.

Study of Datopotamab Deruxtecan, Durvalumab, and Carboplatin for Advanced Non-Small Cell Lung Cancer in Patients Without Actionable Genomic Alterations

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Astrazeneca AB

Study of Tamibarotene and Azacitidine Treatment in Newly Diagnosed Adults with RARA-positive Higher-risk Myelodysplastic Syndrome (MDS)

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Syros Pharmaceuticals Inc.

Study of Disitamab Vedotin and Pembrolizumab for Patients with Untreated Advanced Urothelial Cancer Expressing HER2

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Seagen Inc.

Study on the Effectiveness and Safety of Depemokimab vs. Mepolizumab for Adults with Relapsing or Refractory Eosinophilic Granulomatosis with Polyangiitis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Leoben

What the registry says about research in the country

01 Breast Cancer Research

Advanced clinical trials focusing on hormone receptor-positive breast cancer treatments, including studies of novel therapies for patients with high-risk disease profiles.

  • Node-positive ER+ HER2- breast cancer
  • Advanced breast cancer treatments
  • Endocrine therapy combinations

Multiple studies evaluating innovative therapeutic approaches for improving patient outcomes in early and advanced stages.

02 Lymphoma Studies

Comprehensive research into various types of lymphoma, examining new treatment combinations and comparing their effectiveness to standard therapies.

  • Follicular lymphoma
  • Diffuse Large B-cell Lymphoma
  • Hodgkin Lymphoma

Investigations focus on improving treatment responses while minimizing side effects.

03 Multiple Myeloma Research

Innovative trials exploring multiple myeloma treatments, including maintenance therapy approaches and combination treatments for both newly diagnosed and relapsed cases.

  • Newly diagnosed multiple myeloma
  • Relapsed/Refractory multiple myeloma
  • Combination therapy approaches

Studies aimed at improving treatment outcomes for various stages of the disease.

04 Leukemia & Other Blood Cancers

Research focusing on chronic lymphocytic leukemia and related blood disorders, evaluating novel therapeutic combinations.

  • Recurrent CLL treatments
  • Novel drug combinations
  • Treatment optimization

Trials designed to improve treatment outcomes for patients with recurring disease.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.